Bolt Biotherapeutics (BOLT) News Today → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free BOLT Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 3:55 PM | msn.comLeerink Partners Downgrades Bolt Biotherapeutics (BOLT)May 16 at 8:04 AM | msn.comGuggenheim Downgrades Bolt Biotherapeutics (BOLT)May 15 at 10:04 PM | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTMay 15 at 5:04 PM | finance.yahoo.comBolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...May 15 at 9:54 AM | msn.comWall Street Set to Open Modestly Higher Wednesday as Inflation Dips in AprilMay 15 at 9:54 AM | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bolt Biotherapeutics (BOLT), Laboratory (LH) and Biophytis (OtherBPTSY)May 15 at 9:54 AM | msn.comBolt Biotherapeutics draws downgrades after portfolio shakeupMay 14, 2024 | msn.comBOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024March 25, 2024 | markets.businessinsider.comBolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy RecommendationFebruary 9, 2024 | benzinga.comVivo Opportunity Fund Holdings, L.P.'s Net WorthDecember 27, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)November 20, 2023 | finance.yahoo.comIs Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?November 10, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 7, 2023 | finance.yahoo.comBolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceOctober 24, 2023 | markets.businessinsider.comBolt Biotherapeutics: Buy Rating Justified by Promising Clinical Results and Strong Financial OutlookOctober 19, 2023 | markets.businessinsider.comBolt Biotherapeutics: First Patient Dosed In Clinical Trial Of BDC-3042October 18, 2023 | benzinga.comBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual MeetingOctober 18, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual MeetingOctober 16, 2023 | finance.yahoo.comBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023September 28, 2023 | markets.businessinsider.comBolt Biotherapeutics' BDC-1001 Gets FDA Orphan Drug Designation To Treat Gastric CancersSeptember 12, 2023 | finance.yahoo.comBolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042August 9, 2023 | finance.yahoo.comBolt Biotherapeutics Second Quarter 2023 Earnings: Misses ExpectationsAugust 8, 2023 | finance.yahoo.comBolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comBolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerJuly 31, 2023 | finance.yahoo.comBolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023July 19, 2023 | msn.comAfter COVID, a Continued Push for Diversity in Clinical TrialsJune 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Bolt Biotherapeutics (BOLT)May 30, 2023 | finance.yahoo.comBioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseasesMay 25, 2023 | finance.yahoo.comBolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual MeetingMay 12, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For May 12, 2023May 11, 2023 | finance.yahoo.comBolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMarch 30, 2023 | msn.comLooking Into Bolt Biotherapeutics's Return On Capital EmployedFebruary 28, 2023 | finance.yahoo.comBolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare ConferenceFebruary 1, 2023 | finance.yahoo.comBolt Biotherapeutics to Present at February Investor ConferencesDecember 14, 2022 | finance.yahoo.comBolt Biotherapeutics Appoints Laura Berner to Board of DirectorsNovember 13, 2022 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.comBolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 7, 2022 | finance.yahoo.comBolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual MeetingNovember 1, 2022 | finance.yahoo.comBiohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?August 26, 2022 | seekingalpha.comBolt Biotherapeutics: A Promised Follow UpAugust 25, 2022 | finance.yahoo.comJ&J (JNJ) Gets EU Nod for Multiple Myeloma Drug TecvayliAugust 25, 2022 | finance.yahoo.comEli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?August 10, 2022 | finance.yahoo.comBolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateJuly 22, 2022 | finance.yahoo.comIs Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?May 28, 2022 | morningstar.comBolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022 | MorningstarMay 27, 2022 | finance.yahoo.comBolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022May 13, 2022 | finance.yahoo.comBolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business HighlightsMay 5, 2022 | finance.yahoo.comArtiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory BoardApril 7, 2022 | finance.yahoo.comBolt Biotherapeutics to Present at 21st Annual Needham Healthcare ConferenceMarch 31, 2022 | benzinga.comBolt Biotherapeutics's Return On Capital Employed Overview Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. BOLT Media Mentions By Week BOLT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BOLT News Sentiment▼-0.110.44▲Average Basic Materials News Sentiment BOLT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BOLT Articles This Week▼80▲BOLT Articles Average Week Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CNSX:BOLT) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA once-in-a-century investment opportunityStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.